Contribute Try STAT+ Today

Middle-income countries have gained greater access to a variety of needed cardiovascular medicines, but remain unable to close the gap with wealthy nations, according to a recent analysis of sales data in dozens of countries.

From 2008 to 2018, the compound annual growth rate for all cardiovascular medicines was nearly 10% in middle-income countries compared with almost 1% in high-income nations. As a result, use of those drugs was six times higher in wealthy countries than lower-income nations in 2018, compared to a 15-fold difference a decade earlier.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.